IN8BIO, INC. Financing Cash Flow
IN8BIO, INC. (INAB) reported Financing Cash Flow of -$246.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- IN8BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$51.00K, a 100.97% decline year-over-year.
- IN8BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$195.00K, a 105.01% decline year-over-year.
- IN8BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $18.49M, a 65.27% increase year-over-year.
- IN8BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $989.00K.
- IN8BIO, INC. net cash provided by (used in) financing activities for fiscal 2025 was $28.64M, a 101.90% increase from fiscal 2024.
- IN8BIO, INC. net cash provided by (used in) financing activities for fiscal 2024 was $14.18M, a 47.55% decline from fiscal 2023.
- IN8BIO, INC. net cash provided by (used in) financing activities for fiscal 2023 was $27.04M, a 200.89% increase from fiscal 2022.
- IN8BIO, INC. net cash provided by (used in) financing activities for fiscal 2022 was $8.99M, a 72.73% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$246.00K 10-Q · filed 2026-08-06 | $18.24M derived: sum of 3 quarters · filed 2026-08-06 | $19.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$195.00K 10-Q · filed 2026-05-07 | $18.29M derived: sum of 2 quarters · filed 2026-05-07 | $19.28M derived: sum of 3 quarters · filed 2026-05-07 | $24.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $18.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $19.48M derived: sum of 2 quarters · filed 2026-03-12 | $24.75M derived: sum of 3 quarters · filed 2026-08-06 | $28.64M 10-K · filed 2026-03-12 |
| 2025-09-30 | $989.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.26M derived: sum of 2 quarters · filed 2026-08-06 | $10.15M 10-Q · filed 2025-11-06 | $21.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $9.16M 10-Q · filed 2026-08-06 | $20.35M derived: sum of 3 quarters · filed 2026-08-06 | $20.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.89M 10-Q · filed 2026-05-07 | $15.08M derived: sum of 2 quarters · filed 2026-05-07 | $14.97M derived: sum of 3 quarters · filed 2026-05-07 | $18.35M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $11.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $11.08M derived: sum of 2 quarters · filed 2026-03-12 | $14.46M derived: sum of 3 quarters · filed 2026-03-12 | $14.18M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$105.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.27M derived: sum of 2 quarters · filed 2025-11-06 | $3.00M 10-Q · filed 2025-11-06 | $16.35M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.10M 10-Q · filed 2025-08-07 | $16.45M derived: sum of 3 quarters · filed 2025-08-07 | $18.11M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$277.00K 10-Q · filed 2025-05-07 | $13.07M derived: sum of 2 quarters · filed 2025-05-07 | $14.73M derived: sum of 3 quarters · filed 2025-05-07 | $26.22M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $13.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $15.00M derived: sum of 2 quarters · filed 2025-03-13 | $26.50M derived: sum of 3 quarters · filed 2025-03-13 | $27.04M 10-K · filed 2025-03-13 |
| 2023-09-30 | $1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $13.14M derived: sum of 2 quarters · filed 2024-11-12 | $13.69M 10-Q · filed 2024-11-12 | $13.44M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $11.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $12.04M 10-Q · filed 2024-08-08 | $11.79M derived: sum of 3 quarters · filed 2024-08-08 | $21.20M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $547.00K 10-Q · filed 2024-05-09 | $294.00K derived: sum of 2 quarters · filed 2024-05-09 | $9.70M derived: sum of 3 quarters · filed 2024-05-09 | $9.64M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$253.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $9.16M derived: sum of 2 quarters · filed 2024-03-14 | $9.09M derived: sum of 3 quarters · filed 2024-03-14 | $8.99M 10-K · filed 2024-03-14 |
| 2022-09-30 | $9.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $9.34M derived: sum of 2 quarters · filed 2023-11-09 | $9.24M 10-Q · filed 2023-11-09 | $8.03M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$169.00K 10-Q · filed 2023-08-10 | -$1.38M derived: sum of 3 quarters · filed 2023-08-10 | $33.81M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$102.00K 10-Q · filed 2023-05-12 | -$1.31M derived: sum of 2 quarters · filed 2023-05-12 | $33.88M derived: sum of 3 quarters · filed 2023-05-12 | $33.29M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $33.98M derived: sum of 2 quarters · filed 2023-03-30 | $33.39M derived: sum of 3 quarters · filed 2023-03-30 | $32.95M 10-K · filed 2023-03-30 |
| 2021-09-30 | $35.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $34.60M derived: sum of 2 quarters · filed 2022-11-10 | $34.17M 10-Q · filed 2022-11-10 | $33.22M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$592.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$1.03M 10-Q · filed 2022-08-12 | -$1.98M derived: sum of 3 quarters · filed 2022-08-12 | $17.64M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$435.00K 10-Q · filed 2022-05-12 | -$1.38M derived: sum of 2 quarters · filed 2022-05-12 | $18.23M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$949.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $18.66M derived: sum of 2 quarters · filed 2022-03-17 | $24.52M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $19.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $25.47M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $5.85M 10-Q · filed 2021-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |